Copyright © Inderes 2011 - present. All rights reserved.
Log in to receive notifications.
  • Latest
  • Markets
    • Morning Review
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Insider Transactions
  • inderesTV
  • Portfolio
  • Forum
  • Premium
  • Femme
  • Learn
    • Investing School
    • Q&A
    • Analysis School
  • About Us
    • Our Coverage
    • Team
Log in to your Inderes Free account to see all free content on this page.
Create account

Cantargia

1.3

 

SEK

 

-1.07 %

1,300 following

CANTA

NASDAQ Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview
Ownership
Investor consensus
-1.07%
-20.73%
-23.57%
-23.08%
-60.63%
-71.43%
-91.78%
-91.22%
-81.6%

Cantargia operates in the pharmaceutical industry and focuses on the development of treatments for cancer and inflammatory diseases. The company researches new therapies that can improve patient outcomes and quality of life. The business is global with a primary presence in Europe and North America. Cantargia was founded in 2004 and is headquartered in Lund, Sweden.

Read more
Market cap
323.2M SEK
Turnover
241.16K SEK
Revenue
EBIT %
P/E
Dividend yield-%
Financial calendar
13.5.
2025

Interim report Q1'25

15.5.
2025

General meeting '25

21.8.
2025

Interim report Q2'25

All
Webcasts
Press releases
3rd party
ShowingAll content types
Regulatory press release4/11/2025, 11:30 AM

Cantargia publishes Annual Report 2024

Cantargia
Regulatory press release4/11/2025, 9:00 AM

Notice of annual general meeting in Cantargia AB (publ)

Cantargia
Regulatory press release4/1/2025, 11:30 AM

Cantargia appoints Morten Lind Jensen as Chief Medical Officer

Cantargia

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio
Create account
Press release3/25/2025, 8:30 PM

Cantargia publishes an abstract on parallel anti-tumor activity and reduction of chemotherapy-induced neuropathy with nadunolimab

Cantargia
Press release3/25/2025, 8:30 PM

Cantargia presents promising preclinical results on a novel IL1RAP-targeting antibody-drug conjugate at AACR 2025.

Cantargia
Press release3/13/2025, 9:00 AM

Cantargia to Participate at Van Lanschot Kempen’s Life Sciences Conference

Cantargia
Regulatory press release3/12/2025, 6:00 AM

First patient enrolled in Cantargia’s leukemia study with nadunolimab

Cantargia
Press release3/10/2025, 1:50 PM

Cantargia’s TRIFOUR phase 2 study investigating nadunolimab in triple negative breast cancer fully recruited

Cantargia
Press release3/6/2025, 9:00 AM

Cantargia to Participate at H.C. Wainwright’s Annual Autoimmune & Inflammatory Virtual Conference

Cantargia
Regulatory press release3/5/2025, 9:30 AM

Cantargia reports promising CAN10 phase 1 data from first multiple dose cohort, and FDA and Key Opinion Leader feedback

Cantargia
Press release2/24/2025, 6:15 PM

Redeye: Cantargia Q4 2024 - Focus on Business Development

Cantargia
Cantargia, Audiocast with teleconference, Q4'24
Webcast2/21/2025, 2:00 PM

Cantargia, Audiocast with teleconference, Q4'24

Cantargia
Regulatory press release2/21/2025, 6:00 AM

Cantargia publishes full year report for 2024

Cantargia
Press release2/19/2025, 9:00 AM

Cantargia to participate in Leerink Partners Global Healthcare Conference

Cantargia
Press release2/13/2025, 7:00 AM

Invitation to presentation of Cantargia’s Year-End report 2024

Cantargia
Regulatory press release2/5/2025, 7:05 PM

Cantargia announces management changes

Cantargia
Regulatory press release1/31/2025, 12:00 PM

Cantargia announces changes in number of shares and votes

Cantargia
Regulatory press release12/23/2024, 5:50 PM

Cantargia announces outcome of the rights issue

Cantargia
Press release12/18/2024, 5:10 PM

Cantargia publishes strong preclinical effects and clinical monotherapy results on nadunolimab in pancreatic cancer in Journal for Immunotherapy of Cancer

Cantargia
Press release12/11/2024, 6:30 PM

Cantargia and GEICAM present updated phase 1 clinical data and new translational results on nadunolimab treatment in advanced triple negative breast cancer at San Antonio Breast Cancer Symposium

Cantargia
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

  • Latest
  • Markets
    • Morning Review
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Insider Transactions
  • inderesTV
  • Portfolio
  • Forum
  • Premium
  • Femme
  • Learn
    • Investing School
    • Q&A
    • Analysis School
  • About Us
    • Our Coverage
    • Team

Privacy preferences

Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.